Welcome to our dedicated page for Ultragenyx Pharm SEC filings (Ticker: RARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ultragenyx Pharmaceutical Inc. filings document a rare-disease biopharmaceutical business with approved medicines, investigational genetic-disease therapies, and a Nasdaq-listed common stock capital structure. Form 8-K reports include operating results, financial guidance, FDA communications, clinical-study data, and risk language tied to drug development, regulatory review, manufacturing, funding needs, competition, and commercialization.
Proxy materials describe annual-meeting matters, board and compensation governance, equity compensation, and stockholder voting. Recent current reports also record restructuring and cost disclosures, employment-related equity plans, and material updates for programs including UX111, UX016, DTX301, DTX401, and GTX-102.
Ultragenyx Pharmaceutical Inc. Chief Financial Officer Howard Horn reported an open-market sale of common stock. On June 1, 2026, he sold 4,653 shares at a price of $23.77 per share. After this transaction, he directly holds 105,689 shares, which include previously reported shares underlying RSUs that remain subject to vesting conditions.
Howard Horn reported proposed sales of Common Stock on Form 144. The filing lists multiple proposed dispositions by Howard Horn with transaction dates in 2026 and earlier, including individual sales of 4,683 shares for $116,606.70 on 05/01/2026 and 4,683 shares for $98,202.51 on 04/01/2026. The entries identify the securities as Performance and Restricted Stock and list Morgan Stanley Smith Barney LLC as the broker.
Ultragenyx Pharmaceutical Inc. director Matthew K. Fust reported receiving equity compensation in the form of both restricted stock units and stock options. He was granted 7,751 shares of Common Stock as Restricted Stock Units under the company’s 2023 Incentive Plan, bringing his direct common stock holdings to 33,696 shares following the award.
He was also granted a stock option for 14,058 shares of Common Stock with an exercise price of $25.80 per share, representing his full reported option position after this grant. Both the RSUs and the stock option vest in full on the earlier of the company’s next Annual Meeting of Stockholders or May 14, 2027.
Ultragenyx Pharmaceutical Inc. director Shehnaaz Suliman reported a mix of equity awards and a share sale. On May 14, 2026, she received 7,751 Restricted Stock Units under the company’s 2023 Incentive Plan and a stock option for 14,058 shares with a $25.80 exercise price, both vesting in full on the earlier of the next Annual Meeting of Stockholders or May 14, 2027. On May 18, 2026, she executed an open-market sale of 5,740 shares of common stock at $25.12 per share, leaving her with 27,951 common shares held directly after the sale.
Ultragenyx Pharmaceutical Inc. director Ray Amrit reported new equity awards consisting of both restricted stock units and stock options. He received 7,751 shares of Common Stock as Restricted Stock Units granted under the Company’s 2023 Incentive Plan. After this award, he directly holds 31,116 shares of Common Stock.
Amrit was also granted a stock option covering 14,058 shares of Common Stock at an exercise price of $25.80 per share, expiring on May 14, 2036. Both the RSUs and the option vest in full on the earlier of the Company’s next Annual Meeting of Stockholders or May 14, 2027, making this a routine, compensation-related acquisition rather than an open-market purchase.
Ultragenyx Pharmaceutical Inc. director Sanders Corazon (Corsee) D. received new equity awards as part of compensation. On May 14, 2026, the director acquired 7,751 shares of common stock through an award of restricted stock units under the company’s 2023 Incentive Plan, bringing direct holdings to 23,095 shares.
On the same date, the director was granted a stock option for 14,058 shares of common stock at an exercise price of $25.80 per share, expiring on May 14, 2036. Both the RSUs and the option vest in full on the earlier of the company’s next annual meeting of stockholders or May 14, 2027, making these routine, time-based equity incentives rather than open-market purchases.
Ultragenyx Pharmaceutical Inc. director Michael Narachi received equity compensation in the form of restricted stock units and options. He was granted 7,751 RSUs that vest in full on the earlier of the company’s next Annual Meeting of Stockholders or May 14, 2027. He also received stock options for 14,058 shares of common stock at an exercise price of $25.80 per share, vesting on the same schedule and expiring on May 14, 2036. Following the RSU grant, his direct common stock holdings increased to 40,441 shares.
Ultragenyx Pharmaceutical Inc. director Daniel G. Welch reported equity awards from the company. He received 7,751 shares of Common Stock as a grant of restricted stock units (RSUs) under the 2023 Incentive Plan, with no cash paid per share, bringing his direct Common Stock holdings to 40,441 shares.
He was also granted a stock option covering 14,058 shares of Common Stock at an exercise price of $25.80 per share, expiring on May 14, 2036. Both the RSUs and the option vest in full on the earlier of the company’s next Annual Meeting of Stockholders or May 14, 2027.
Ultragenyx Pharmaceutical Inc. director Deborah Dunsire received new equity awards as part of her compensation. She was granted 7,751 shares of Common Stock in the form of restricted stock units that vest in full on the earlier of the company’s next Annual Meeting of Stockholders or May 14, 2027. She also received stock options for 14,058 shares of Common Stock at an exercise price of $25.80 per share, expiring on May 14, 2036, with the options vesting on the same schedule. Following these awards, she directly holds 38,566 shares of Common Stock and 14,058 stock options.